Coherus Oncology (CHRS) Treasury Shares (2013 - 2025)

Coherus Oncology (CHRS) has 11 years of Treasury Shares data on file, last reported at $188557.0 in Q4 2025.

• For the quarter ending Q4 2025, Treasury Shares fell 75.46% year-over-year to $188557.0; the trailing twelve-month figure through Dec 2025 stood at $188557.0 (down 75.46% YoY), and the FY2025 full-year result was $188557.0, down 75.46% from the prior year.
• Treasury Shares declined to $188557.0 in Q4 2025, from $768237.0 in the prior quarter.
• In the past five years, Treasury Shares ranged from a high of $2.3 million in Q4 2022 to a low of $188557.0 in Q4 2025.
• A 5-year average of $1.4 million and a median of $1.7 million in 2023 frame the typical range for Treasury Shares.
• Across the five-year window, Treasury Shares jumped 82.61% in 2021 and plunged 75.46% in 2025, its largest moves.
• Tracing CHRS's Treasury Shares over 5 years: stood at $1.8 million in 2021, then grew by 26.55% to $2.3 million in 2022, then dropped by 26.0% to $1.7 million in 2023, then slumped by 55.51% to $768237.0 in 2024, then sank by 75.46% to $188557.0 in 2025.
• Business Quant data shows CHRS's Treasury Shares at $188557.0 in Q4 2025, $768237.0 in Q4 2024, and $1.7 million in Q4 2023.